Sun Pharma Share Price in Focus; Company Enters Agreement on U.S. Medicines Pricing and Access

Sun Pharmaceutical Industries has joined other drugmakers at a White House ceremony following agreements with the U.S. government aimed at improving access to affordable medicines for patients in the country.  

Under its agreement, Sun Pharma will extend Most Favored Nation pricing to state Medicaid programmes and apply the same pricing approach to future launches of innovative medicines. In return, the agreement provides for a delay of Section 232 tariffs on innovative pharmaceutical products for more than two years. Other terms have not been disclosed.  

Sun Pharma Expands U.S. Focus 

The U.S. has become an important part of Sun Pharma's business, with the company investing across clinical development, sales, marketing, and manufacturing of APIs and finished products.  

The company said it ranks second in the U.S. by prescriptions in dermatology. Its operations there cover dermatology and immunology, cutaneous oncology and ophthalmology, alongside its generics and consumer health businesses.  

The U.S. contributes around 27% of Sun Pharma's global revenue and is its largest market for innovative medicines. Earlier this year, the company also signed a definitive agreement to acquire Organon & Co. for an enterprise value of $11.75 billion.  

About Sun Pharma 

Sun Pharmaceutical Industries operates across innovative medicines, generics and consumer healthcare. The company has a presence in more than 100 countries, with manufacturing facilities spread across five continents.  

Its global innovative medicines portfolio includes dermatology, ophthalmology and onco-dermatology products.  

Read More: Marine Electricals Share Price in Focus; Receives ₹398.81 Crore Orders from PDG and Classic Electric! 

Sun Pharma Share Price Performance  

As of 01 September 2026, at 11:20 AM, Sun Pharmaceutical Industries share price is trading at ₹1,934.80 per share, reflecting a decline of 2.52% from the previous trading session. 

Conclusion 

The agreement gives Sun Pharma a defined pricing commitment in the U.S. while the company continues to build its presence in innovative medicines and manufacturing. Its U.S. business remains a major part of the group, contributing about 27% of global revenue. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.